- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00945087
Experimental Phage Therapy of Bacterial Infections
Experimental Phage Therapy of Drug-resistant Bacterial Infections, Including MRSA Infections
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bacterial infections of different tissues and organs that prove incurable by antibiotics are a serious clinical problem. Bacteriophages (phages) are bacterial viruses which attack, multiply within, and then destroy bacteria. They can efficiently destroy bacteria which have acquired resistance to antibiotics and which cause life-threatening infections. The method of treating bacterial infections using phages has been known since the beginning of the 20th century. This experimental treatment enables the use of phage preparations under the rules of a therapeutic experiment (on the basis of the respective Polish regulations) in cases where no effective available therapy exists or the use of the targeted drug is contraindicated. It is not a research study.
The bacteriophage preparations which are used in the treatment procedures contain phages from the Bacteriophage Collection of the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences in Wrocław. For each patient only specific formulations of single phage or a phage mixture that are active against the pathogenic bacterial strain or strains isolated from the patient are used for the treatment.The isolation of live bacterial pathogen from the patient is necessary to carry out a phage-typing procedure to determine if the preparation of an active formulation is possible which is a prerequisite for receiving the treatment.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andrzej Górski, M.D. Ph.D.
- Phone Number: +48 71-3709905
- Email: agorski@ikp.pl
Study Contact Backup
- Name: Ryszard Międzybrodzki, M.D. Ph.D.
- Phone Number: +48 71-3709901
- Email: cm@iitd.pan.wroc.pl
Study Locations
-
-
-
Wrocław, Poland, 53-114
- Recruiting
- Phage Therapy Unit at the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences
-
Sub-Investigator:
- Ryszard Międzybrodzki, M.D. Ph.D.
-
Principal Investigator:
- Andrzej Górski, M.D. Ph.D.
-
Sub-Investigator:
- Wojciech Fortuna, M.D. Ph.D.
-
Sub-Investigator:
- Krzysztof Szufnarowski, M.D.
-
Sub-Investigator:
- Sławomir Letkiewicz, M.D. Ph.D.
-
Sub-Investigator:
- Beata Weber-Dąbrowska, Ph.D.
-
Sub-Investigator:
- Paweł Rogóż, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or over.
- Men and women of reproductive age must use contraception during and one month after the therapy. Women of reproductive age must have negative result of a pregnancy test before beginning of the treatment.
- Signed informed consent.
- Antibiotic therapy-resistant, chronic, symptomatic bacterial infection of the skin, subcutaneous tissue, bone, bone marrow, joints, fistulas, wounds, bedsores, genital and/or urinary tract, digestive tract, middle ear, sinuses, tonsils, upper and lower respiratory tract, or a state in which a targeted antibiotic therapy is impossible to carry out due to other medical reasons.
- A putative pathogenic bacteria such as Staphylococcus, Enterococcus, Escherichia, Citrobacter, Enterobacter, Klebsiella, Shigella, Salmonella, Serratia, Proteus, Pseudomonas, Stenotrophomonas, Acinetobacter, Burkholderia, or Morganella present in the site of the said infection as confirmed by the result of microbiological culture.
- Ineffective antibiotic therapy of said infection and/or antibiogram-confirmed multidrug resistance of a putative pathogenic bacteria such as Staphylococcus, Enterococcus, Escherichia, Citrobacter, Enterobacter, Klebsiella, Shigella, Salmonella, Serratia, Proteus, Pseudomonas, Stenotrophomonas, Acinetobacter, Burkholderia, or Morganella.
- The presence in the Bacteriophage Collection of the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences of a phage able to lyse a bacterial strain cultured from a patient in the Bacteriophage Collection of the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences (positive result of a phage-typing procedure).
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Malabsorption syndrome, allergy to food or animal protein, or advanced hepatic insufficiency when it is impossible to apply the phage preparation using other route than oral.
- Allergy to components of phage preparations.
- A health condition which does not allow conducting the experimental therapy in the opinion of the qualifying physician.
Study Plan
How is the study designed?
Collaborators and Investigators
Investigators
- Study Director: Andrzej Górski, M.D. Ph.D., Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OTF-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Infections
-
Sir Run Run Shaw HospitalUniversity of BirminghamUnknown
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineWithdrawn
-
GlaxoSmithKlineWithdrawn
Clinical Trials on Bacteriophage preparation
-
Intralytix, Inc.Johns Hopkins University; Icahn School of Medicine at Mount SinaiRecruiting
-
Southwest Regional Wound Care CenterCompleted
-
Tashkent Pediatric Medical InstituteActive, not recruiting
-
BiomX, Inc.Active, not recruitingCystic Fibrosis | Chronic Pseudomonas Aeruginosa InfectionUnited States, Israel, Spain, Czechia, Netherlands
-
Centre Hospitalier Universitaire de NīmesPherecydes PharmaNot yet recruitingDiabetic Foot | Staphylococcal InfectionsFrance
-
Queen Astrid Military HospitalCompletedBacterial Infections
-
University of South FloridaUnknownPrimary Immune Deficiency DiseasesUnited States
-
The Affiliated Hospital of Qingdao UniversityEnrolling by invitationPharmacokinetics | SafetyChina
-
Colorado State UniversityMetabiomics Corp; George Mason UniversityCompletedGastrointestinal Disorder, Functional
-
National Institute of Allergy and Infectious Diseases...CompletedImmunoproliferative DisorderUnited States